Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in
patients with acute coronary syndrome (ACS) and in those undergoing percutaneous …

The widespread use of clopidogrel alone or in combination with aspirin has significantly
benefited patients with acute coronary syndrome who are managed medically or by …

Objectives: This study sought to determine whether known genetic, drug, dietary,
compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully …

Importance of the field: The use of clopidogrel and aspirin has become standard therapy in
patients with acute coronary syndromes and stent implantation. However, concern arises …

Acute coronary syndromes (ACS) remain life-threatening disorders, which are associated
with high morbidity and mortality. Dual antiplatelet therapy with aspirin and clopidogrel has …

Objectives: This study assessed the effect of pharmacogenetics on the antiplatelet effect of
clopidogrel. Background: Variability in clopidogrel response might be influenced by …

The inhibition of platelet function by antiplatelet therapy determines the improvement of the
survival of patients with clinically evident cardiovascular disease. Clopidogrel in …

Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery
disease patients undergoing a percutaneous coronary intervention. However, approximately …

Clopidogrel, an antiplatelet agent, prevents platelet aggregation by inhibiting the adenosine
disphosphate (ADP) P2Y12 receptor, which is located on the platelet surface. Although dual …

Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to
prevent recurrent ischemic event occurrence in coronary artery disease patients. Generally …